122 related articles for article (PubMed ID: 35076180)
1. Flexible Etherified and Esterified Triphenylethylene Derivatives and Their Evaluation on ER-positive and Triple-Negative Breast Cancer Cell Lines.
Hassan AS; Wober J; Vollmer G; Abadi AH; Ahmed NS
ChemMedChem; 2022 Apr; 17(7):e202100720. PubMed ID: 35076180
[TBL] [Abstract][Full Text] [Related]
2. Synthesis of novel flexible tamoxifen analogues to overcome CYP2D6 polymorphism and their biological evaluation on MCF-7 cell line.
Ahmed NS; Wober J
Drug Dev Res; 2020 Jun; 81(4):444-455. PubMed ID: 31916635
[TBL] [Abstract][Full Text] [Related]
3. Design and synthesis of novel tamoxifen analogues that avoid CYP2D6 metabolism.
Ahmed NS; Elghazawy NH; ElHady AK; Engel M; Hartmann RW; Abadi AH
Eur J Med Chem; 2016 Apr; 112():171-179. PubMed ID: 26896706
[TBL] [Abstract][Full Text] [Related]
4. Manipulating Estrogenic/Anti-Estrogenic Activity of Triphenylethylenes towards Development of Novel Anti-Neoplastic SERMs.
Elnakib HE; Ramsis MM; Albably NO; Vector MA; Weigand JJ; Schwedtmann K; Wober J; Zierau O; Vollmer G; Abadi AH; Ahmed NS
Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830456
[TBL] [Abstract][Full Text] [Related]
5. Design, synthesis, and metabolite identification of Tamoxifen esterase-activatable prodrugs.
Elbagoury RM; Shenouda MA; Elnakib HE; Wober J; Abadi AH; Ahmed NS
Bioorg Chem; 2023 Feb; 131():106303. PubMed ID: 36455483
[TBL] [Abstract][Full Text] [Related]
6. Structure-Activity Relationships of Triphenylethylene Derivatives and Their Evaluation as Anticancer and Antiviral Agents.
Ahmed NS; El-Nakib HE; Ramsis MM; Albably NO; Wober J; Weigand JJ; Schwedtmann K; Zierau O; Abadi AH
ACS Omega; 2023 Jul; 8(29):25903-25923. PubMed ID: 37521647
[TBL] [Abstract][Full Text] [Related]
7. Tamoxifen resistance and metastasis of human breast cancer cells were mediated by the membrane-associated estrogen receptor ER-α36 signaling in vitro.
Gu W; Dong N; Wang P; Shi C; Yang J; Wang J
Cell Biol Toxicol; 2017 Apr; 33(2):183-195. PubMed ID: 27837347
[TBL] [Abstract][Full Text] [Related]
8. Design and synthesis of novel flexible ester-containing analogs of tamoxifen and their evaluation as anticancer agents.
Elghazawy NH; Engel M; Hartmann RW; Hamed MM; Ahmed NS; Abadi AH
Future Med Chem; 2016; 8(3):249-56. PubMed ID: 26898104
[TBL] [Abstract][Full Text] [Related]
9. CB1 and CB2 receptors are novel molecular targets for Tamoxifen and 4OH-Tamoxifen.
Prather PL; FrancisDevaraj F; Dates CR; Greer AK; Bratton SM; Ford BM; Franks LN; Radominska-Pandya A
Biochem Biophys Res Commun; 2013 Nov; 441(2):339-43. PubMed ID: 24148245
[TBL] [Abstract][Full Text] [Related]
10. Design, synthesis and biological evaluation of novel triaryl (Z)-olefins as tamoxifen analogues.
Abdellatif KR; Belal A; Omar HA
Bioorg Med Chem Lett; 2013 Sep; 23(17):4960-3. PubMed ID: 23860592
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of proliferation of estrogen receptor‑positive MCF‑7 human breast cancer cells by tamoxifen through c‑Jun transcription factors.
Xu Y; Zou ST; Zhu R; Li W; Gu CW; Wei SH; Xie JM; Wu HR
Mol Med Rep; 2013 Apr; 7(4):1283-7. PubMed ID: 23404426
[TBL] [Abstract][Full Text] [Related]
12. Investigation of the mechanism of tamoxifen-stimulated breast tumor growth with nonisomerizable analogues of tamoxifen and metabolites.
Wolf DM; Langan-Fahey SM; Parker CJ; McCague R; Jordan VC
J Natl Cancer Inst; 1993 May; 85(10):806-12. PubMed ID: 8487325
[TBL] [Abstract][Full Text] [Related]
13. Estrogen receptor-α36 is involved in development of acquired tamoxifen resistance via regulating the growth status switch in breast cancer cells.
Li G; Zhang J; Jin K; He K; Zheng Y; Xu X; Wang H; Wang H; Li Z; Yu X; Teng X; Cao J; Teng L
Mol Oncol; 2013 Jun; 7(3):611-24. PubMed ID: 23499324
[TBL] [Abstract][Full Text] [Related]
14. Cross-resistance of triphenylethylene-type antiestrogens but not ICI 182,780 in tamoxifen-stimulated breast tumors grown in athymic mice.
Lee ES; Schafer JM; Yao K; England G; O'Regan RM; De Los Reyes A; Jordan VC
Clin Cancer Res; 2000 Dec; 6(12):4893-9. PubMed ID: 11156249
[TBL] [Abstract][Full Text] [Related]
15. Rationale for sequential tamoxifen and anticancer drugs in adjuvant setting for patients with node- and receptor-positive breast cancer.
Kim R; Tanabe K; Emi M; Uchida Y; Osaki A; Toge T
Int J Oncol; 2005 Apr; 26(4):1025-31. PubMed ID: 15753998
[TBL] [Abstract][Full Text] [Related]
16. Nitrosourea and nitrosocarbamate derivatives of the antiestrogen tamoxifen as potential estrogen receptor-mediated cytotoxic agents in human breast cancer cells.
Wei LL; Katzenellenbogen BS; Robertson DW; Simpson DM; Katzenellenbogen JA
Breast Cancer Res Treat; 1986; 7(2):77-90. PubMed ID: 3719114
[TBL] [Abstract][Full Text] [Related]
17. Design, synthesis, and in-silico study of novel triarylethylene analogs with dual anti-estrogenic and serotonergic activity.
Mostafa T; Albeir M; Wober J; Abadi A; Salama I; Ahmed NS
Drug Dev Res; 2024 Feb; 85(1):e22127. PubMed ID: 37877739
[TBL] [Abstract][Full Text] [Related]
18. Keratinocyte growth factor (KGF) induces tamoxifen (Tam) resistance in human breast cancer MCF-7 cells.
Chang HL; Sugimoto Y; Liu S; Ye W; Wang LS; Huang YW; Lin YC
Anticancer Res; 2006; 26(3A):1773-84. PubMed ID: 16827106
[TBL] [Abstract][Full Text] [Related]
19. Tamoxifen synergizes with 4-(E)-{(4-hydroxyphenylimino)-methylbenzene, 1,2-diol} and 4-(E)-{(p-tolylimino)-methylbenzene-1,2-diol}, novel azaresveratrol analogs, in inhibiting the proliferation of breast cancer cells.
Ronghe A; Chatterjee A; Bhat NK; Padhye S; Bhat HK
Oncotarget; 2016 Aug; 7(32):51747-51762. PubMed ID: 27351134
[TBL] [Abstract][Full Text] [Related]
20. Tamoxifen reverses epithelial-mesenchymal transition by demethylating miR-200c in triple-negative breast cancer cells.
Wang Q; Cheng Y; Wang Y; Fan Y; Li C; Zhang Y; Wang Y; Dong Q; Ma Y; Teng YE; Qu X; Liu Y
BMC Cancer; 2017 Jul; 17(1):492. PubMed ID: 28724364
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]